214 309

Cited 7 times in

Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma

DC Field Value Language
dc.contributor.author김진우-
dc.contributor.author나준채-
dc.contributor.author한웅규-
dc.date.accessioned2022-08-23T00:17:04Z-
dc.date.available2022-08-23T00:17:04Z-
dc.date.issued2022-06-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189351-
dc.description.abstractClear cell renal cell carcinoma (ccRCC) alters metabolic signals frequently, leading to mitochondrial dysfunction, such as increase of glycolysis and accumulation of lipid. Sirtuin3 (SIRT3) is a key factor for the regulation of both mitochondrial integrity and function. SIRT3 is downregulated and contributes in both cancer development and progression in ccRCC. The aim of this study is to investigate SIRT3-regulated mitochondrial biogenesis in ccRCC. SIRT3 overexpression alone reduced glucose uptake rate and enhanced membrane potential in mitochondria. ccRCC with overexpressed SIRT3 further improved the lethal effects when combined with anticancer drugs (Resveratrol, Everolimus and Temsirolimus). Cell viability was markedly decreased in a dose-dependent manner when treated with resveratrol or mTOR inhibitors in SIRT3 overexpressing ccRCC. In conclusion, SIRT3 improved mitochondrial functions in ccRCC through metabolic reprogramming. Mitochondrial reprogramming by SIRT3 regulation improves the sensitivity to anticancer drugs. The combination of SIRT3 and resveratrol functioned synergistically lethal effect in ccRCC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPublic Library of Science-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntineoplastic Agents* / metabolism-
dc.subject.MESHAntineoplastic Agents* / pharmacology-
dc.subject.MESHCarcinoma, Renal Cell* / drug therapy-
dc.subject.MESHCarcinoma, Renal Cell* / genetics-
dc.subject.MESHCarcinoma, Renal Cell* / metabolism-
dc.subject.MESHDrug Resistance-
dc.subject.MESHHumans-
dc.subject.MESHKidney Neoplasms* / drug therapy-
dc.subject.MESHKidney Neoplasms* / genetics-
dc.subject.MESHKidney Neoplasms* / metabolism-
dc.subject.MESHMitochondria / metabolism-
dc.subject.MESHResveratrol / metabolism-
dc.subject.MESHResveratrol / pharmacology-
dc.subject.MESHSirtuin 3* / genetics-
dc.subject.MESHSirtuin 3* / metabolism-
dc.titleMitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorYoung-Ran Gu-
dc.contributor.googleauthorJinu Kim-
dc.contributor.googleauthorJoon Chae Na-
dc.contributor.googleauthorWoong Kyu Han-
dc.identifier.doi10.1371/journal.pone.0269432-
dc.contributor.localIdA06158-
dc.contributor.localIdA04742-
dc.contributor.localIdA04308-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid35671305-
dc.contributor.alternativeNameKim, Jinu-
dc.contributor.affiliatedAuthor김진우-
dc.contributor.affiliatedAuthor나준채-
dc.contributor.affiliatedAuthor한웅규-
dc.citation.volume17-
dc.citation.number6-
dc.citation.startPagee0269432-
dc.identifier.bibliographicCitationPLOS ONE, Vol.17(6) : e0269432, 2022-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.